Gilead’s Plan? Cash In on CAR-T – Motley Fool
STAT |
Gilead’s Plan? Cash In on CAR–T
Motley Fool The Swiss biopharma Goliath Novartis is the only other drug developer to have a CAR–T that’s pending approval from the FDA. In Kite Pharma’s case, it’s awaiting an FDA decision on axi-cel, a CAR–T that’s under priority review for use in patients with B … Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsementBusiness Insider Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT The Promising New Cancer Treatment Behind Gilead’s $11 Billion DealFox Business Barron’s –Reuters –Markets Insider –Zacks Investment Research all 244 news articles » |
STAT |
Gilead’s Plan? Cash In on CAR–T
Motley Fool The Swiss biopharma Goliath Novartis is the only other drug developer to have a CAR–T that’s pending approval from the FDA. In Kite Pharma’s case, it’s awaiting an FDA decision on axi-cel, a CAR–T that’s under priority review for use in patients with B … Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsementBusiness Insider Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT The Promising New Cancer Treatment Behind Gilead’s $11 Billion DealFox Business Barron’s –Reuters –Markets Insider –Zacks Investment Research all 244 news articles » |
|
The Promising New Cancer Treatment Behind Gilead’s $11 Billion …
Fox Business Gilead Sciences Inc.’s planned acquisition of Kite Pharma Inc. underscores the promise of a new type of cancer therapy that is on the brink of becoming … |
Wall Street Journal (subscription) |
FDA to Expand Its Authority Over Stem–Cell Treatment Facilities
Wall Street Journal (subscription) The Food and Drug Administration is stepping up oversight of fledgling medical treatments that aim to harness the potential of stem cells—as well as some businesses that the agency said were selling unapproved and possibly harmful treatments. The FDA … |
Reuters |
FDA steps up scrutiny of stem cell therapies
Reuters A small number of “unscrupulous actors” have seized on the promise of regenerative medicine and stem cell therapies to mislead patients based on unproven, and in some cases, dangerously dubious products, the FDA said on Monday. (bit.ly/2iB4Xls). |
|
Biotech stocks surge on Gilead’s Kite Pharma acquisition
MarketWatch The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T–cell therapy, or CAR-T, which uses a patient’s immune T–cells and re-engineers them to better fight cancer. Juno, Bluebird and … |